These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Management of hemophilia]. Laurian Y. Rev Prat; 1989 Dec 21; 39(30):2669-73. PubMed ID: 2515580 [Abstract] [Full Text] [Related]
3. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies. Engelfriet CP, Reesink HW, Mannucci PM, Gringeri A, Ingerslev J, Brettler DB, Mauser-Bunschoten EP, Negrier C, Berntorp E, Smith OP, Shapiro AD. Vox Sang; 2000 Dec 21; 78(4):256-61. PubMed ID: 10970234 [No Abstract] [Full Text] [Related]
4. [New viewpoints in the treatment of hemophilia]. Göbel U. Dtsch Med Wochenschr; 1973 Sep 28; 98(39):1814-6. PubMed ID: 4583442 [No Abstract] [Full Text] [Related]
10. Immunogenicity and immune tolerance coagulation Factors VIII and IX. Rup B. Dev Biol (Basel); 2003 Oct 28; 112():55-9. PubMed ID: 12762504 [Abstract] [Full Text] [Related]
12. The past and future of haemophilia: diagnosis, treatments, and its complications. Peyvandi F, Garagiola I, Young G. Lancet; 2016 Jul 09; 388(10040):187-97. PubMed ID: 26897598 [Abstract] [Full Text] [Related]
19. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII]. Hrubisková K. Folia Haematol Int Mag Klin Morphol Blutforsch; 1980 Jul 01; 107(4):672-82. PubMed ID: 6162735 [Abstract] [Full Text] [Related]